These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1346 related articles for article (PubMed ID: 22217937)

  • 1. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.
    Ross-Innes CS; Stark R; Teschendorff AE; Holmes KA; Ali HR; Dunning MJ; Brown GD; Gojis O; Ellis IO; Green AR; Ali S; Chin SF; Palmieri C; Caldas C; Carroll JS
    Nature; 2012 Jan; 481(7381):389-93. PubMed ID: 22217937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
    Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
    Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.
    Hurtado A; Holmes KA; Geistlinger TR; Hutcheson IR; Nicholson RI; Brown M; Jiang J; Howat WJ; Ali S; Carroll JS
    Nature; 2008 Dec; 456(7222):663-6. PubMed ID: 19005469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
    Nardone A; Qiu X; Spisak S; Nagy Z; Feiglin A; Feit A; Cohen Feit G; Xie Y; Font-Tello A; Guarducci C; Hermida-Prado F; Syamala S; Lim K; Munoz Gomez M; Pun M; Cornwell M; Liu W; Ors A; Mohammed H; Cejas P; Brock JB; Freedman ML; Winer EP; Fu X; Schiff R; Long HW; Metzger Filho O; Jeselsohn R
    Cancer Res; 2022 Oct; 82(20):3673-3686. PubMed ID: 35950920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response.
    Fu X; Huang C; Schiff R
    Breast Cancer Res; 2011 Apr; 13(2):307. PubMed ID: 21575280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A co-ordinated interaction between CTCF and ER in breast cancer cells.
    Ross-Innes CS; Brown GD; Carroll JS
    BMC Genomics; 2011 Dec; 12():593. PubMed ID: 22142239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ELF5 modulates the estrogen receptor cistrome in breast cancer.
    Piggin CL; Roden DL; Law AMK; Molloy MP; Krisp C; Swarbrick A; Naylor MJ; Kalyuga M; Kaplan W; Oakes SR; Gallego-Ortega D; Clark SJ; Carroll JS; Bartonicek N; Ormandy CJ
    PLoS Genet; 2020 Jan; 16(1):e1008531. PubMed ID: 31895944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To bind or not to bind--FoxA1 determines estrogen receptor action in breast cancer progression.
    Watters RJ; Benos PV; Oesterreich S
    Breast Cancer Res; 2012 Jun; 14(3):312. PubMed ID: 22713214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
    Yamaguchi N; Nakayama Y; Yamaguchi N
    J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ER regulates an evolutionarily conserved apoptosis pathway.
    Liu Z; Chen S
    Biochem Biophys Res Commun; 2010 Sep; 400(1):34-8. PubMed ID: 20691160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
    Xu G; Chhangawala S; Cocco E; Razavi P; Cai Y; Otto JE; Ferrando L; Selenica P; Ladewig E; Chan C; Da Cruz Paula A; Witkin M; Cheng Y; Park J; Serna-Tamayo C; Zhao H; Wu F; Sallaku M; Qu X; Zhao A; Collings CK; D'Avino AR; Jhaveri K; Koche R; Levine RL; Reis-Filho JS; Kadoch C; Scaltriti M; Leslie CS; Baselga J; Toska E
    Nat Genet; 2020 Feb; 52(2):198-207. PubMed ID: 31932695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
    Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
    Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXA1 is a key determinant of estrogen receptor function and endocrine response.
    Hurtado A; Holmes KA; Ross-Innes CS; Schmidt D; Carroll JS
    Nat Genet; 2011 Jan; 43(1):27-33. PubMed ID: 21151129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1.
    Robinson JL; Macarthur S; Ross-Innes CS; Tilley WD; Neal DE; Mills IG; Carroll JS
    EMBO J; 2011 Jun; 30(15):3019-27. PubMed ID: 21701558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.
    Wang C; Mayer JA; Mazumdar A; Brown PH
    Breast Cancer Res Treat; 2012 Jun; 133(2):487-500. PubMed ID: 21947652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 19. A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
    Blawski R; Toska E
    Cancer Res; 2022 Oct; 82(20):3668-3670. PubMed ID: 36245246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.